This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?
This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?
The summer book club started in 2015, with one of the best books we have done in book club, Atul Gawande's Being Mortal. I think it should be required reading for all physicians. So now, in 2025, it is the NephJC Summer Book’s tenth anniversary (which represents our eleventh book). The history has been rich:
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
La hipertensión arterial sigue siendo uno de los principales factores de riesgo modificables para enfermedad cardiovascular y enfermedad renal crónica. Las nuevas guías AHA/ACC 2025 han actualizado aspectos fundamentales sobre la prevención, la evaluación y el tratamiento de la hipertensión, con implicaciones directas para la práctica nefrológica.
Revisa el resumen visual creado por Dr Sejal Lakhani
visual abstract, Visual Abstract, sejal lakhani, Hypertension, HTN, ACC/AHA, 2025
New updated guidance on hypertension including screening for secondary causes, use of renal denervation, hypertension and pregnancy, risk assessment, monitoring and treatment.
Check out this wonderful VA by Dr Sejal Lakhani
Check out the summary on HiLo chat, done by NephJC intern Shellie Fravel.
Check out the summary on ACHIEVE chat, done by NephJC intern Janany Sabescumar.
¿La espironolactona será la heroína que conquiste el corazón en hemodiálisis?
Descúbrelo en la travesía del ensayo ACHIEVE y únete a la discusión en #NephJC.
Does spironolactone decrease cardiovascular disease and heart failure hospitalizations in patients on dialysis?
Check out this crisp VA by Dr Akshaya Jayachandran.
The summer book club started in 2015, with one of the best books we have done in book club, Atul Gawande's Being Mortal. I think it should be required reading for all physicians. So now, in 2025, it is the NephJC Summer Book’s tenth anniversary (which represents our eleventh book). The history has been rich:
Aunque sabemos que el fósforo elevado se asocia consistentemente con mayor mortalidad y eventos cardiovasculares, aún no existe evidencia definitiva de que bajarlo de forma agresiva cambie el pronóstico.
Revisemos el resumen visual del estudio HiLo, creado Sejal Lakhani que evaluó objetivos altos vs. bajos de fósforo sérico en pacientes en hemodiálisis.
Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis?
Check out this crisp VA by Dr Sejal Lakhani
Check out the summary on eGFR diference chat, done by NephJC intern Bogdan Agavriloaei
Basado en los datos del estudio CRIC, este análisis profundiza en si esa discordancia (TFGe dif) es solo “ruido”… o una señal clínica que hemos estado ignorando.
Echale un vistazo al resumen visual realizado por el equipo de internos de #NephJC Dr Sai Vani Yellampalli y Akshaya Jayachandran
Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing.
Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran. Great team work!!!
